| | 1191237-69-0 Basic information More.. |
| Product Name: | GS-441524 | | Synonyms: | 2-C-(4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZIN-7-YL)-2,5-ANHYDRO-3,4-O-(1-METHYLETHYLIDENE)-D-ALTRONONITRI;D-Altrononitrile, 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-;2-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-Altrononitrile;GS441525;(2R,3R,4S,5R)-2-(4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZIN-7-YL)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDRO;GS-441524(EVO984);Remdesivir Impurity 6;S-441524 | | CAS: | 1191237-69-0 | | MF: | C12H13N5O4 | | MW: | 291.26 | | EINECS: | 200-001-8 | | Mol File: | 1191237-69-0.mol |  |
Use
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it[1]), but GS-441524 has been found to be effective treatment for FIP and is widely used despite no official FDA approval due to Gileads refusal to license this drug for veterinary use.
- GS-441524
-
- US $10.00 / ASSAYS
- 2024-09-22
- CAS:1191237-69-0
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 10 ton
- GS-441524
-
- US $0.00 / G
- 2024-09-21
- CAS:1191237-69-0
- Min. Order: 1G
- Purity: 99%
- Supply Ability: 20
|
|
1191237-69-0
Recommend Suppliers |
|